Background: Post-transplantational diabetes mellitus (PTDM) is a serious metabolic complication that may follow renal transplantation. The expression of chemokine (C-C motif) ligand 5 (CCL5) is inversely related to pancreatic β-cell function; thus, specific CCL5 gene polymorphisms are considered to be risk factors for diabetes. In this study, we investigated the association between CCL5 gene polymorphisms and the occurrence of PTDM in Korean patients who had undergone renal transplants. Methods: A total of 311 patients who had received kidney transplants without a prior history of diabetes were included. Three single nucleotide polymorphisms (SNPs) of the CCL5 gene were genotyped from genomic DNA with direct sequencing. Results: PTDM developed in 56 patients (18.0%). The results showed that the allele frequencies of CCL5 gene polymorphisms, rs2107538*T, rs2280789*C and rs3817655*A were significantly higher in the patients with PTDM than in those without PTDM. In multiple logistic regression analysis, 3 SNPs (rs2107538, rs2280789 and rs3817655) of the CCL5 gene were significantly associated with the development of PTDM in the codominant 2 and recessive models. Among haplotypes of the 3 polymorphisms, the frequency of the TCA haplotype was significantly higher in patients with PTDM than in those without PTDM. Conclusions: Our results indicated that genetic polymorphisms of the CCL5 gene were associated with PTDM, suggesting that the CCL5 gene might confer susceptibility to PTDM in patients who receive renal transplants.

Keywords:
CCL5 polymorphism, Renal transplantation, Post-transplantational diabetes mellitus
1.
Rodrigo E, Fernandez-Fresnedo G, Valero R, Ruiz JC, Pinera C, Palomar R, Gonzalez-Cotorruelo J, Gomez-Alamillo C, Arias M: New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006;17:S291–S295.
2.
Davidson JA, Wilkinson A: New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist’s view. Diabetes Care 2004;27:805–812.
3.
Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001;71:1417–1423.
4.
Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC: Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007;30:609–615.
5.
Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
6.
Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H: Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005;54(Suppl 2):S11–S17.
7.
Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G, Woolf N, Campbell IL, Sarvetnick N: Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999;162:2511–2520.
8.
Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R, Kolb H, Roep BO, Mortensen HB, Schloot NC: Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 2008;128:57–65.
9.
Herder C, Peltonen M, Koenig W, Kraft I, Muller-Scholze S, Martin S, Lakka T, Ilanne-Parikka P, Eriksson JG, Hamalainen H, Keinanen-Kiukaanniemi S, Valle TT, Uusitupa M, Lindstrom J, Kolb H, Tuomilehto J: Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 2006;55:2340–2346.
10.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S: Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000;121:437–443.
11.
Zhernakova A, Alizadeh BZ, Eerligh P, Hanifi-Moghaddam P, Schloot NC, Diosdado B, Wijmenga C, Roep BO, Koeleman BP: Genetic variants of RANTES are associated with serum RANTES level and protection for type 1 diabetes. Genes Immun 2006;7:544–549.
12.
Yao TC, Tsai YC, Huang JL: Association of RANTES promoter polymorphism with juvenile rheumatoid arthritis. Arthritis Rheum 2009;60:1173–1178.
13.
Vogiatzi K, Voudris V, Apostolakis S, Kochiadakis GE, Thomopoulou S, Zaravinos A, Spandidos DA: Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. Thromb Res 2009;124:84–89.
14.
Krüger B, Böger CA, Obed A, Farkas S, Hoffmann U, Banas B, Fischereder M, Krämer BK: RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection. Clin Transplant 2007;21:385–390.
15.
Konta T, Emi M, Toriyama S, Ariumi H, Ishii M, Takasaki S, Ikeda A, Ichikawa K, Shibata Y, Takabatake N, Takeishi Y, Kato T, Kawata S, Kubota I: Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. J Hum Genet 2008;53:267–274.
16.
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 2002;296:2225–2229.
17.
Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Togashi H, Matsuura S, Tada H, Suzuki T, Habuchi T: Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. Transplant Proc 2005;37:1865–1867.
18.
Kang ES, Kim MS, Kim YS, Hur KY, Han SJ, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC: A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 2008;31:63–68.
19.
Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, Hur KY, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC: A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008;57:1043–1047.
20.
Böger CA, Fischereder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M, Banas B, Krüger B, Riegger GA, Krämer BK: RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 2005;183:121–129.
21.
Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, Marz W, Vassalli G: Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 2004;25:1438–1446.
22.
Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Spengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH, Huang SK: Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000;164:1612–1616.
23.
Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178–185.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.